Opinion|Videos|January 1, 2025

Examining Elafibranor as a Treatment Option for PBC

Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.

Video content above is prompted by the following:

  1. Elafibranor received accelerated approval based on findings from the ELATIVE study. What are the key efficacy insights from this trial?
  2. Elafibranor was also demonstrated to have long-term safety and efficacy at 3 years. How does this durability affect your clinical decision-making?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME